224 related articles for article (PubMed ID: 14665360)
1. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis.
Joudi FN; Smith BJ; O'Donnell MA; Konety BR
Urology; 2003 Dec; 62(6):1083-8. PubMed ID: 14665360
[TBL] [Abstract][Full Text] [Related]
2. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
3. Practice pattern of non-muscle invasive bladder cancer in Japan, Korea and Taiwan: A Web-based survey.
Choo SH; Nishiyama H; Kitamura H; Chen CH; Pu YS; Lee HL; Jeong BC; Kim SI
Int J Urol; 2019 Dec; 26(12):1121-1127. PubMed ID: 31512280
[TBL] [Abstract][Full Text] [Related]
4. Managing superficial bladder cancer: an overview.
Soloway MS
Urology; 1992 Dec; 40(6 Suppl):5-10. PubMed ID: 1466119
[TBL] [Abstract][Full Text] [Related]
5. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
6. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
[TBL] [Abstract][Full Text] [Related]
7. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
8. Contemporary management of superficial bladder cancer.
Pow-Sang JM; Seigne JD
Cancer Control; 2000; 7(4):335-9. PubMed ID: 10895127
[TBL] [Abstract][Full Text] [Related]
9. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
10. Ranking Important Factors for Using Postoperative Chemotherapy in Nonmuscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
Cary C; Tong Y; Linsell S; Ghani K; Miller DC; Weiner M; Koch MO; Perkins SM; Zimet G
J Urol; 2022 Feb; 207(2):293-301. PubMed ID: 34551594
[TBL] [Abstract][Full Text] [Related]
11. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
[TBL] [Abstract][Full Text] [Related]
12. Intravesical therapy for superficial bladder cancer.
Malkowicz SB
Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
[TBL] [Abstract][Full Text] [Related]
13. Intravesical immunotherapy for superficial bladder cancer.
Said MT; Abomelha MS; Orkubi SA
Saudi Med J; 2002 Dec; 23(12):1458-61. PubMed ID: 12518191
[TBL] [Abstract][Full Text] [Related]
14. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
16. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder.
Zietman AL; Grocela J; Zehr E; Kaufman DS; Young RH; Althausen AF; Heney NM; Shipley WU
Urology; 2001 Sep; 58(3):380-5. PubMed ID: 11549485
[TBL] [Abstract][Full Text] [Related]
17. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
Huben RP
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
[TBL] [Abstract][Full Text] [Related]
18. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
19. Superficial bladder carcinoma. Factors affecting the natural history.
Fitzpatrick JM
World J Urol; 1993; 11(3):142-7. PubMed ID: 8401631
[TBL] [Abstract][Full Text] [Related]
20. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
